CD300A and neoplasm: In non-small cell lung cancer (NSCLC), the expression of CD300a is elevated, and its high expression is negatively correlated with NSCLC tumor suppression, potentially through inhibition of the Wnt/β-catenin signaling pathway, thereby slowing tumor progression [51].